Synthesis method of 3-(5, 5-dimethyl-1, 3, 2-dioxoborane-2-yl)-N-phenylpropanamide
By carrying out a reduction-cross coupling reaction in the presence of a nickel catalyst and nitrogen ligand, the problems of cumbersome synthesis steps and high cost in the prior art have been solved, and the efficient and economical synthesis of 3-(5,5-dimethyl-1,3,2-dioxoboron-2-yl)-N-phenylpropionamide has been achieved.
Patent Information
- Application Number
- CN202411000937.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
Existing techniques for synthesizing 3-(5,5-dimethyl-1,3,2-dioxoboron-2-yl)-N-phenylpropionamide require the use of pre-prepared organometallic reagents and stoichiometric oxidants, which are cumbersome and costly, making it difficult to achieve efficient synthesis.
3-(5,5-dimethyl-1,3,2-dioxoboron-2-yl)-N-phenylpropionamide was synthesized in a one-pot process by a reduction cross-coupling reaction in an organic solvent using a nickel catalyst, nitrogen ligand, and reducing agent. This simplified the reaction steps and improved the product yield.
The method achieves efficient and economical synthesis of 3-(5,5-dimethyl-1,3,2-dioxoborane-2-yl)-N-phenylpropionamide, reducing raw material loss, saving time and energy, and is simple and safe to operate.
Smart Images

Figure CN118908988A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of organic synthesis, and particularly relates to a method for synthesizing 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide. Background Art
[0002] Amide bonds are the basic structural units in organic synthesis, so the research on this compound has attracted the attention of many scientific researchers. At the same time, this structure exists in a large number of drug molecules. For example, acetaminophen is the in vivo metabolite of phenacetin. By inhibiting the prostaglandin synthase in the hypothalamic thermoregulatory center, the synthesis and release of prostaglandins PGE1, bradykinin and histamine are reduced, resulting in a decrease in the central temperature setting point. Through neural regulation, peripheral vasodilation and sweating are induced to achieve an antipyretic effect; this structure also exists in lidocaine, which is a local anesthetic and antiarrhythmic drug. It is a derivative of cocaine, but it does not have the addictive and hallucinogenic components of cocaine. It has good surface penetration and can be injected or used for surface anesthesia; at the same time, this structure is also used in atorvastatin, a selective inhibitor of HMG-CoA reductase. It can reduce lipoprotein and plasma cholesterol levels by inhibiting HMG-CoA reductase and cholesterol biosynthesis in the liver, and increase the uptake and catabolism of low-density lipoprotein (LDL) by increasing the number of low-density lipoprotein (LDL) receptors on the surface of hepatocytes.
[0003] In addition, the structure is also used in pesticides. For example, tetrachlorantraniliprole is a new compound developed with chlorantraniliprole as the lead. Compared with chlorantraniliprole, its chemical structure replaces the original methyl group with chlorine at the 4-position of the benzene ring, and introduces chlorine at the 3-position of the pyridine ring. It belongs to the o-formylaminobenzamide class of ryanodine receptor modulators. It has high activity, good rapidity, long duration, and low toxicity to mammals. It can be widely used in crops such as rice, fruit trees, and vegetables. Therefore, the synthesis and modification of transition metal-catalyzed amide compounds are of great scientific research value and market application value. In addition, organic boron compounds are an important part of synthetic chemistry and have extremely wide applications. In particular, alkyl boron compounds are very important synthetic precursors that can be converted into various valuable functional groups with high efficiency and low energy consumption. At the same time, these organic boron compounds are also widely used in fields such as materials science and medicinal chemistry. For example, in the field of medicinal chemistry, bortezomib is a non-steroidal anti-inflammatory drug commonly used to treat inflammatory diseases such as rheumatoid arthritis, rheumatoid arthritis, and ankylosing spondylitis.
[0004] In addition, since the combination of different organoboron compounds has a great influence on biological activity, organoboron compounds are widely used in the field of pesticide research. Organoboron compounds pesticides can form chemical bonds with active centers in target organisms, thereby destroying metabolic reactions and causing biological death. This is of great significance to the improvement of modern agricultural production and environmental protection.
[0005] Summary of the invention
[0006] The invention provides a reduction cross-coupling reaction of N-phenylacrylamide and diboronic acid neopentyl glycol ester under the catalysis of metal nickel, which can obtain 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide with biological and pharmacological activities and medicinal values, effectively avoids the use of prefabricated organic metal reagents, equal amounts of bases and stoichiometric oxidants, and synthesizes 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide in a direct and easy-to-operate method.
[0007] The specific plan is as follows:
[0008]
[0009] A method for synthesizing 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide, comprising: using N-phenylacrylamide shown in Formula 1 and neopentyl glycol diborate shown in Formula 2 to mix with an organic solvent in the presence of a transition metal catalyst, a nitrogen ligand and a reducing agent, and performing a reduction cross-coupling reaction to synthesize 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide shown in Formula 3;
[0010] The method of the invention can realize the one-pot generation of 3-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-N-phenylpropionamide, reducing the reaction steps, thereby improving the product yield; the synthetic method has multiple raw material acquisition pathways and has high economic benefits.
[0011] Preferably, the reaction is carried out under the protection of an inert gas, argon, which has a good protection effect.
[0012] Preferably, the synthesis occurs in the presence of a transition metal catalyst, a nitrogen ligand and an organic solvent.
[0013] Preferably, the transition metal catalyst is a nickel catalyst; and the nitrogen ligand is bipyridine.
[0014] Preferably, the nickel catalyst is ethylene glycol dimethyl ether nickel bromide with high catalytic activity.
[0015] Preferably, the organic solvent is N,N-dimethylacetamide which is not easily hydrolyzed and has low toxicity.
[0016] Preferably, in the reaction, the molar ratio of N-phenylacrylamide shown in Formula 1, neopentyl glycol diborate shown in Formula 2 and the catalyst is 1:3:0.1; and the reaction temperature is 80°C.
[0017] Preferably, the method of the present invention can generate 3-(5,5-dimethyl-1,3,2-dioxaborolane-2-yl)-N-phenylpropionamide having the following structure:
[0018]
[0019] Under the action of transition metal catalyst ethylene glycol dimethyl ether nickel bromide, reducing agent zinc powder and nitrogen ligand bipyridine, N-phenylacrylamide and neopentyl glycol diborate undergo a reductive cross-coupling reaction to finally prepare 3-(5,5-di-methyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide.
[0020] The raw materials used in the synthesis method of the present invention are all cheap and have diversified acquisition methods, thus having high economic benefits;
[0021] The present invention adopts a one-pot synthesis method, which has fewer reaction steps, reduces the loss of raw materials and saves reaction time, thereby improving product yield and reaction efficiency;
[0022] The operation steps required by the present invention are relatively simple, and no extreme heating or cooling is required. The reaction can be performed under normal pressure, which is safe, convenient and low in energy consumption.
[0023] Instruction Manual
[0024] The accompanying drawings are hydrogen and carbon nuclear magnetic resonance spectra of the products of each embodiment. The serial numbers of the accompanying drawings correspond to the serial numbers of the embodiments. Figure A is a hydrogen nuclear magnetic resonance spectrum, and Figure B is a carbon nuclear magnetic resonance spectrum. Figure 1A is the hydrogen nuclear magnetic resonance spectrum of the product obtained in Example 1, Figure 1B The carbon nuclear magnetic resonance spectrum of the product obtained in Example 1 is shown in FIG. Specific embodiments
[0025] In order to facilitate those skilled in the art to understand, the concept of the present invention is further described below in conjunction with the embodiments. The specific description of the following embodiments is not a limitation of the present invention, but is only for the convenience of those skilled in the art to understand the technical solution. Various raw materials involved in the specification are purchased from the market, or through simple synthesis, other drugs are purchased from Anaiji, Bi De, Sigma-Aldrich, Acros, Alfa Aesar, Adams-beta or J&K., and the nuclear magnetic resonance spectrometer model is Bruker 400M.
[0026] Example 1
[0027] In a glove box, under argon atmosphere at room temperature, ethylene glycol dimethyl ether nickel bromide (0.01mmol, 0.1 equivalent), bipyridine (0.011mmol, 0.11 equivalent) and N, N-dimethylacetamide (0.25mL) were added to a microwave tube equipped with a stirrer. After 30 minutes, manganese powder (0.1mmol, 1.0 equivalent), 1-((bromo(cyclopropyl)methyl)sulfoxide)-4-methylbenzene (0.1mmol, 1.0 equivalent) and iodobenzene (0.3mmol, 3.0 equivalent) were added, and then the microwave tube was sealed and taken out of the glove box. The microwave tube was placed at 80°C and the reaction mixture was stirred for 8 hours. After 8 hours, ethyl acetate (2mL) was added to the resulting solution, filtered and concentrated to obtain a crude product. The crude product was separated by column chromatography (petroleum ether: ethyl acetate = 1:3) to obtain 3-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-N-phenylpropanamide (17.3 mg, 82% yield). The hydrogen spectrum and carbon spectrum nuclear magnetic resonance spectra of the product are shown in Figure A and Figure B, respectively, and the spectrum data are as follows: 1 H NMR (400MHz, CDCl3) δ: 7.61 (s, 1H), 7.51-7.49 (d, 2H), 7.32-7.26 (m, 2H), 7.09- 7.05(t, 1H), 3.63(s, 4H), 2.47-2.44(t, 2H), 1.11-1.07(t, 2H), 0.97(s, 6H)ppm. 13 C{ 1 H} NMR (101MHz, CDCl3) δ: 172.8, 138.3, 128.9, 123.8, 119.5, 72.0, 32.2, 21.8ppm.
Claims
1. A method for synthesizing 3-(5,5-dimethyl-1,3,2-dioxaborolane-2-yl)-N-phenylpropionamide, characterized in that: N-phenylacrylamide shown in Formula 1 and neopentyl glycol diborate shown in Formula 2 are mixed with an organic solvent in the presence of a transition metal catalyst, a nitrogen ligand and a reducing agent to carry out a reductive cross-coupling reaction to synthesize 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide shown in Formula 3.
2. The synthesis method according to claim 1, characterized in that The synthesis occurs in the presence of a transition metal catalyst, a nitrogen ligand, a reducing agent and an organic solvent.
3. The synthesis method according to claim 2, characterized in that The transition metal catalyst is a nickel catalyst.
4. The synthesis method according to claim 3, characterized in that The nickel catalyst is ethylene glycol dimethyl ether nickel bromide.
5. The synthesis method according to claim 1, characterized in that The reaction was carried out under the protection of inert gas argon.
6. The synthesis method according to claim 1, characterized in that The nitrogen ligand is bipyridine.
7. The synthesis method according to claim 1, characterized in that The organic solvent is N,N-dimethylacetamide.
8. The synthesis method according to claim 1, characterized in that In the reaction, the molar ratio of N-phenylacrylamide shown in Formula 1, neopentyl glycol diborate shown in Formula 2 and the catalyst is 1:3:0.
1.
9. The synthesis method according to claim 1, characterized in that The N-phenylacrylamide, neopentyl glycol diborate and the product 3-(5,5-dimethyl-1,3,2-dioxaborolane-2-yl)-N-phenylpropionamide are shown in the following table: The invention discloses a method for synthesizing 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide, and belongs to the field of organic synthesis. The invention adopts N-phenylacrylamide shown in Formula 1 and neopentyl glycol diborate shown in Formula 2 to be mixed with an organic solvent in the presence of a transition metal catalyst, a nitrogen ligand and a reducing agent to carry out a reduction cross-coupling reaction to synthesize 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide shown in Formula 3. The synthesis method of the invention is simple and easy to operate, and has a very important significance for synthesizing 3-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-N-phenylpropionamide.
Citation Information
Patent Citations
Synthesis method of diaryl boric acid ester compound
CN116253755A
